Experts Highlight ASH 2025 Findings Transforming Cancer Treatments

The 2025 ASH Annual Meeting and Exposition showcased pivotal research that could significantly alter treatment practices for various hematologic malignancies. Experts highlighted studies that revealed the beneficial effects of low-intensity regimens in treating acute myeloid leukemia (AML), expanded options for CAR T-cell therapy in marginal zone lymphoma (MZL), and the promise of bispecific antibodies in multiple myeloma. These findings suggest a shift in how these cancers may be managed in clinical settings.

Key Findings from the PARADIGM Study

One of the standout studies, the PARADIGM trial, evaluated the combination of venetoclax (marketed as Venclexta) and azacitidine against more intensive chemotherapy regimens. According to Dr. Andorsky, the results indicated that the combination therapy may not only be better tolerated but could also provide significant clinical benefits for many patients. This randomized data aligns with long-held suspicions in the field, making it a potential game-changer in AML treatment.

Dr. Jen pointed out that the findings might extend the use of azacitidine and venetoclax beyond their current indications, particularly for patients older than 75 years. The median age of participants in the study was notably higher, suggesting a broader applicability of these treatments moving forward.

Dr. Arora emphasized the significance of the PARADIGM trial, stating that it supports a transition from traditional treatments where fit patients typically receive the 7+3 chemotherapy regimen. The trial’s data suggests that using hypomethylating agents (HMAs) along with venetoclax in fit, newly diagnosed patients can lead to improved outcomes, although it is essential to consider the trial’s exclusion criteria, which included patients with specific mutations.

Innovative Therapies for Marginal Zone Lymphoma and Myeloma

The introduction of liso-cel, a CAR T-cell therapy, has also made waves in the management of relapsed or refractory MZL. Dr. Kamdar noted that long-term follow-up data from the TRANSCEND FL trial demonstrated remarkable benefits for patients with high tumor burdens and early progression. On December 4, 2025, the FDA approved liso-cel for use in the third-line setting, marking an important step forward for patients who have limited options.

In the realm of multiple myeloma, the phase 3 MajesTEC-3 trial presented data on teclistamab, a bispecific antibody designed to target both BCMA and CD3. Dr. Cerchione highlighted the impressive response rates and the potential to reduce the use of dexamethasone, which is typically associated with adverse effects. The study suggests that the treatment could enhance patient quality of life while maintaining efficacy.

Emerging from these findings is a potential new standard of care for patients experiencing early relapse. The LINKER-MM4 trial is currently investigating linvoseltamab, another bispecific antibody, as a monotherapy for both transplant-eligible and -ineligible patients newly diagnosed with multiple myeloma, further indicating a shift towards innovative immune therapies in this space.

Dr. Biran discussed the potential of post-transplant therapies, specifically the BCMA T-cell engager linvoseltamab, which achieved nearly a 100% minimal residual disease negativity rate in a recent trial. This underscores the importance of ongoing research into immune therapies and their role in altering disease progression.

The studies presented at ASH 2025 not only underscore significant advancements in the treatment of hematologic cancers but also point toward an evolving understanding of patient management. As the medical community digests these findings, the potential for transformative changes in treatment paradigms becomes increasingly clear.